Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Conagra Brands Inc (CAG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Conagra Brands Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.76 (market cap $4.49B), while Conagra Brands Inc trades at $13.87 (market cap $6.71B). The key difference: Conagra Brands Inc is the larger of the two by market cap, and Conagra Brands Inc pays a 9.98% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | CAG | |
|---|---|---|
Market Cap | $4.49B | $6.71B |
Sector | Health | Consumer Staples |
52-Week High | $28.06 | $20.65 |
52-Week Low | $20.06 | $12.58 |
Enterprise Value | $3.69B | $13.99B |
Dividend Yield | — | 9.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Conagra Brands (CAG) trades at $14.035, down 2.06% on the day, with mixed technical signals and a neutral overall stance. The stock shows modest valuation metrics with a P/E of 10.06 and P/B of 0.81, but faces profitability challenges with a negative net income margin of -0.39%. Recent earnings have been inconsistent, missing estimates in two of the last three quarters. A high dividend yield of approximately 10% is under scrutiny amid concerns over debt levels and slowing growth under new leadership, with the company set to report Q4 earnings on July 15, 2026.
The outlook for CAG is cautious, with potential upside from defensive positioning and dividend income, but significant risks from earnings volatility, high leverage, and dividend sustainability concerns. Investor sentiment is divided, with analysts predominantly neutral, reflecting uncertainty around the company's ability to navigate operational headwinds and debt management effectively.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Conagra Brands Inc
Conagra Brands is a packaged food company that operates predominantly in the United States (over 90% of revenue and profits). It has a significant presence in the freezer aisle, with brands such as Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Other popular brands include Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. While the majority of revenue is sold into the U.S. retail channel, 9% of fiscal 2022 sales were to the food-service channel, down from 11% in fiscal 2019 due to the pandemic.
Read more on CAG →
